Clinical implications from recent trials and new guidelines for stroke prevention in atrial fibrillation

European Cardiology

Volumn 8, Issue 3, 2012, Pages 174-178

  Müssigbrodt, Andreas ^a   Hindricks, Gerhard ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

American college of cardiology; American heart association; Anticoagulation; Apixaban; Atrial fibrillation; European society of cardiology; Guidelines; Rivaroxaban; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; RIVAROXABAN; WARFARIN;

AIR EMBOLISM; ARTICLE; BLEEDING DISORDER; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CARDIAC EQUIPMENT; CARDIOVASCULAR RISK; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONSENSUS DEVELOPMENT; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; HEALTH CARE ORGANIZATION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); OPEN HEART SURGERY; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURGICAL STAPLING; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 84872813500     PISSN: 17583756     EISSN: 17583764     Source Type: Journal    
DOI: 10.15420/ecr.2012.8.3.174     Document Type: Article

References (31)

1. Lloyd-Jones DM, Wang TJ, Leip EP, et al., Lifetime risk for development of atrial fibrillation: the Framingham Heart Study, Circulation, 2004;110:1042-6.
2. Wolf PA, Abbott RD, Kannel WB, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, 1991;22:983-8.
3. Camm AJ, Kirchhof P, Lip GY, et al., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 2010;31:2369-429.
4. Skanes AC, Healey JS, Cairns JA, et al., Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control, Can J Cardiol, 2012;28:125-36.
5. Fuster V, Ryden LE, Cannom DS, et al., ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society, Circulation, 2006;114:257-354.
6. Wann LS, Curtis AB, Ellenbogen KA, et al., 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, 2011;123:1144-50.
7. Lip GY, Nieuwlaat R, Pisters R, et al., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation, Chest, 2010;137:263-72.
8. Olesen JB, Lip GY, Hansen ML, et al., Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study, BMJ, 2011;342:d124.
9. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY, The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study, Thromb Haemost, 2012;107(6):1172-9.
10. Pieri A, Lopes TO, Gabbai AA, Stratification with CHA2DS2-VASc score is better than CHADS2 score in reducing ischemic stroke risk in patients with atrial fibrillation, Int J Stroke, 2011;6:466.
11. Mant J, Hobbs FD, Fletcher K, et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, Lancet, 2007;370:493-503.
12. Alberts MJ, Bhatt DL, Smith SC, et al., Risk factors and outcomes for patients with vascular disease and serious bleeding events, Heart, 2011;97:1507-12.
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al., Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 2009;361:1139-51.
14. Patel MR, Mahaffey KW, Garg J, et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 2011;365:883-91.
15. Granger CB, Alexander JH, McMurray JJ, et al., Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 2011;365:981-92.
16. Chan KE, Lazarus JM, Thadhani R, Hakim RM, Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients, J Am Soc Nephrol, 2009;20:872-81.
17. Calkins H, Kuck KH, Cappato R, et al., 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society, Heart Rhythm, 2012;9:632-96.
18. Saad EB, d'Avila A, Costa IP, et al., Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score
19. Welles CC, Whooley MA, Na B, et al., The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study, Am Heart J, 2011;162:555-61.
20. Hindricks G, Pokushalov E, Urban L, et al., Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial, Circ Arrhythm Electrophysiol, 2010;3:141-7.
21. Ferro JM, Cardioembolic stroke: an update, Lancet Neurol, 2003;2(3):177-88.
22. Klein AL, Grimm RA, Murray RD, et al., Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation, N Engl J Med, 2001;344:1411-20.
23. Healey JS, Crystal E, Lamy A, et al., Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke, Am Heart J, 2005;150:288-93.
24. Whitlock RP, Healey JS, Connolly SJ, Left atrial appendage occlusion does not eliminate the need for warfarin, Circulation, 2009;120:1927-32.
25. Bayard YL, Omran H, Neuzil P, et al., PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study, EuroIntervention, 2010;6:220-6.
26. Sick PB, Schuler G, Hauptmann KE, et al., Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation, J Am Coll Cardiol, 2007;49:1490-5.
27. Park JW, Bethencourt A, Sievert H, et al., Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience, Catheter Cardiovasc Interv, 2011;77:700-6.
28. Holmes DR, Reddy VY, Turi ZG, et al., Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial, Lancet, 2009;374:534-42.
29. Reddy VY, Holmes D, Doshi SK, et al., Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry, Circulation, 2011;123:417-24.
30. Kirchhof P, Lip GY, Van Gelder IC, et al., Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference, Europace, 2012;14:8-27.
31. Lip GY, Lim HS, Atrial fibrillation and stroke prevention, Lancet Neurol, 2007;6:981-93.